Saturday 17 October 2026
Export LIANY’s income statement to Excel — free account
LianBio Sponsored ADR
LIANY Healthcare Biotechnology
0.05
0.00
0.00%
Follow LIANY
| Dec '23 | Sep '23 | Jun '23 | Mar '23 | Older periods | |
|---|---|---|---|---|---|
| 70.96% | (32.42%) | (29.51%) | (33.36%) |
+8 more TTM periods Free account |
|
| 66.19% | (28.62%) | (26.39%) | (29.78%) | ||
ROIC |
(450.47%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
53.56% | (37.51%) | (33.79%) | (39.06%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
2.40 | (0.78) | (0.79) | (0.98) | |
Free Cash Flow |
258.79 | (83.99) | (84.87) | (105.24) | |
Capital Expenditures |
(0.37) | (0.46) | (1.24) | (1.52) | |
| Other line items | |||||
Cash ROIC |
22.53% | (17.20%) | (16.23%) | (18.76%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.30 | 0.79 | 0.17 | |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 1,838.43 | 564.13 | 1,743.92 | |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.01 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
— | (10.75) | (12.19) | (19.13) | |
Operating CF/Net income |
0.83 | 0.95 | 0.97 | 0.97 | |
Depreciation/Fixed assets |
0.63 | 0.55 | 0.49 | 0.37 | |
Capex/Depreciation |
(0.28) | (0.36) | (0.99) | (1.44) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
2.40 | (0.78) | (0.78) | (0.97) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates